6C91

Structure of GRP94 with a resorcinylic inhibitor.

6C91 の概要

• エントリーDOI: 10.2210/pdb6c91/pdb
• 分子名称: Endoplasmin, SULFATE ION, 5-[2-(1-benzyl-1H-imidazol-2-yl)ethyl]-4,6-dichlorobenzene-1,3-diol, ... (5 entities in total)
• 機能のキーワード: chaperone, inhibitor, endoplasmin, chaperone-inhibitor complex, chaperone/inhibitor
• 由来する生物種: Canis lupus familiaris (Dog); 詳細
• タンパク質・核酸の鎖数: 2
• 化学式量合計: 54889.49

構造登録者

Que, N.L.S.,Gewirth, D.T. (登録日: 2018-01-25, 公開日: 2018-04-18, 最終更新日: 2024-03-13)

主引用文献

Que, N.L.S.,Crowley, V.M.,Duerfeldt, A.S.,Zhao, J.,Kent, C.N.,Blagg, B.S.J.,Gewirth, D.T.
Structure Based Design of a Grp94-Selective Inhibitor: Exploiting a Key Residue in Grp94 To Optimize Paralog-Selective Binding.
J. Med. Chem., 61:2793-2805, 2018

PubMed Abstract: Grp94 and Hsp90, the ER and cytoplasmic hsp90 paralogs, share a conserved ATP-binding pocket that has been targeted for therapeutics. Paralog-selective inhibitors may lead to drugs with fewer side effects. Here, we analyzed 1 (BnIm), a benzyl imidazole resorcinylic inhibitor, for its mode of binding. The structures of 1 bound to Hsp90 and Grp94 reveal large conformational changes in Grp94 but not Hsp90 that expose site 2, a binding pocket adjacent to the central ATP cavity that is ordinarily blocked. The Grp94:1 structure reveals a flipped pose of the resorcinylic scaffold that inserts into the exposed site 2. We exploited this flipped binding pose to develop a Grp94-selective derivative of 1. Our structural analysis shows that the ability of the ligand to insert its benzyl imidazole substituent into site 1, a different side pocket off the ATP binding cavity, is the key to exposing site 2 in Grp94.

PubMed: 29528635
DOI: 10.1021/acs.jmedchem.7b01608

実験手法

X-RAY DIFFRACTION (2.895 Å)